Wirsing von König C H, Finger H
Institut für Hygiene und Laboratoriumsmedizin, Städtische Krankenanstalten Krefeld.
Immun Infekt. 1995 Aug;23(4):125-9.
Acellular vaccines against pertussis could be developed because various virulence factors of B. pertussis have been characterized. Acellular pertussis vaccines should retain the efficacy but have lower side effects, as compared to the conventional whole-cell vaccine. Lacking any correlate of antibacterial resistance, the efficacy of the vaccines had to be tested in large field trials. Such trials have been conducted and are being conducted in various European and in one African country. These trials used different designs, and various different vaccines were tested. All available efficacy data show that acellular pertussis vaccine can effectively protect against typical pertussis. It also seems probable that the efficacy of vaccines, which contain more than two pertussis components may be better than a vaccine containing pertussis toxoid or pertussis toxoid with filamentous hemagglutinin. A three-component acellular pertussis vaccine has been licensed for use in primary vaccination in infants in Germany in early 1995.
由于百日咳博德特氏菌的各种毒力因子已被鉴定出来，因此可以开发针对百日咳的无细胞疫苗。与传统的全细胞疫苗相比，无细胞百日咳疫苗应保留疗效，但副作用更低。由于缺乏任何抗菌抗性的相关指标，疫苗的疗效必须在大型现场试验中进行测试。此类试验已在欧洲多个国家以及一个非洲国家开展并仍在进行。这些试验采用了不同的设计，测试了各种不同的疫苗。所有可得的疗效数据表明，无细胞百日咳疫苗能够有效预防典型的百日咳。似乎还可能的是，含有两种以上百日咳成分的疫苗的疗效可能优于含有百日咳毒素或百日咳毒素与丝状血凝素的疫苗。一种三组分无细胞百日咳疫苗于1995年初在德国获得许可用于婴儿的初次疫苗接种。
